Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.24.2.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash $ 8,365 $ 65,222
Accounts receivable, net 0 740
Grant receivable 109,736 76,266
Prepaid expenses 53,909 44,891
Total current assets 172,010 187,119
Property and equipment, net 38,105 50,943
Right to use assets 218,046 97,278
Other assets:    
Patents, net 8,438 9,027
Deposits, long term 41,936 44,520
Total other assets 50,374 53,547
Total assets 478,535 388,887
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,173,120 and $1,683,453, respectively 5,330,053 4,649,179
Lease liability, short term 38,491 122,732
Derivative liability 80,190 53,460
Notes payable, net of debt discount of $180,599 and $354,730, respectively 1,000,881 606,750
Notes payable, related parties, net of debt discount of $0 and $77,295, respectively 865,353 999,088
Total current liabilities 7,314,968 6,431,209
Long term liabilities:    
Economic Injury Disaster loan, long term 71,754 72,466
Royalty obligation, net of discount of $4,662,246 and $4,899,354, related parties 4,059,854 3,822,746
Lease liability, long term 179,555 10,945
Deferred revenue, long term 0 4,045
Total liabilities 11,626,131 10,341,411
Preferred stock, no par value, 600,000 authorized    
Common stock, $0.001 par value; 750,000,000 shares authorized, 9,783,074 and 8,674,029 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 9,783 8,674
Common stock subscribed 100,000 100,009
Additional paid in capital 69,424,316 68,149,029
Accumulated deficit (80,557,140) (78,103,018)
Total deficit attributable to BioCorRx Inc. (11,001,425) (9,823,690)
Non-controlling interest (146,171) (128,834)
Total deficit (11,147,596) (9,952,524)
Total liabilities and deficit 478,535 388,887
Series A Convertible Preferred Stock [Member]    
Preferred stock, no par value, 600,000 authorized    
Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023 16,000 16,000
Series B Convertible Preferred Stock [Member]    
Preferred stock, no par value, 600,000 authorized    
Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023 $ 5,616 $ 5,616